Arvinas (ARVN) said Friday that data from the first-in-human clinical trial of ARV-102 demonstrated substantial reduction of leucine-rich repeat kinase 2, or LRRK2, a multifunctional protein that has been primarily implicated in Parkinson's disease.
ARV-102 was generally safe and well tolerated with no serious adverse events reported after single or multiple doses, the company said.
At a single oral dose of at least 60 mg, and once daily repeated oral doses of at least 20 mg, ARV-102 achieved greater than 50% LRRK2 reduction in the cerebral spinal fluid and greater than 90% LRRK2 reduction in the peripheral blood mononuclear cells.
The company said its findings support continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction and a phase 1 trial in patients with Parkinson's disease has been initiated and is currently enrolling.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.